|
1. BIOLOGIE
|
|
|
|
1.4 BIOLOGIE - TECHNOS
|
|
|
|
4.12 BIOPSIES LIQUIDES
|
|
|
|
4.9 DÉP., DIAG. & PRONO. - SEIN
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
|
5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
|
|
|
|
5.2.2 PHARMA - FUSIONS & ACQUISITIONS
|
|
|
|
5.2.3 PHARMA - ÉCONOMIE
|
|
|
Joining AI Drug Discovery Race, Erasca Adds $22M For Cancer Work [Xconomy]
|
|
|
|
|
|
The system helps comb through publicly available and proprietary information on cancer genomics, cancer drug targets, and biological pathways of interest. The hope is with those insights, and more broadly, machine learning and automation, Erasca can pinpoint “what parts of discovery we can just fundamentally change or accelerate.”
|
|
|
|
|
|
|
|
5.3 TRAITEMENTS - FDA, EMA, NICE...
|
|
|
A New FDA Commissioner, Suddenly [In The Pipeline]
|
|
|
|
|
|
The XBI biotech index staggered the minute the news came out, and it’s down even more today. That’s many billions of dollars of market cap disappearing before your eyes, and it’s due both to the loss of Gottlieb and the fear of what might come after. As I’ve said many times, the FDA is not the real roadblock in this business. It’s biology. More specifically, it’s our lack of understanding of biology. Lowering standards will do nothing to help that at all.
|
|
|
|
|
|
|
U.S. FDA chief tough on e-cigarettes steps down abruptly [Reuters]
|
|
|
|
|
|
Gottlieb ran into fierce opposition from anti-regulation groups, such as Americans for Tax Reform, and former FDA officials, who said the agency’s regulatory efforts would destroy thousands of jobs. A coalition of these groups wrote Trump last month asking him to “immediately halt the Food and Drug Administration’s aggressive regulatory assault” on e-cigarette businesses.
|
|
|
|
|
|
|
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
|
|
|
|
5.4 TRAITEMENTS - ECONOMIE
|
|
|
|
6. LUTTE CONTRE LES CANCERS
|
|
|
|
6.1 OBSERVATION
|
|
|
|
6.10 POLITIQUES
|
|
|
W.H.O. Chief Plans to Reorganize a Vast Bureaucracy [NY Times]
|
|
|
|
|
|
A fundamental rewrite of the W.H.O.’s charter would be needed to fix what is sometimes called the agency’s “birth defect.” Its regional officers are independently elected, and have large staffs and budgets they are reluctant to cut. Some even resist cooperating with headquarters in Geneva. That has had serious consequences.
|
|
|
|
|
|
|
|
WHO unveils sweeping reforms in drive towards “triple billion” targets [WHO]
|
|
|
|
|
|
The changes are designed to support countries in achieving the ambitious “triple billion” targets that are at the heart of WHO’s strategic plan for the next five years: one billion more people benefitting from universal health coverage (UHC); one billion more people better protected from health emergencies; and one billion more people enjoying better health and well-being.
|
|
|
|
|
|
|
6.10.1 POLITIQUES (USA)
|
|
|
|
6.11 PATIENTS
|
|
|
|
6.12 ETHIQUE
|
|
|
|
|
6.4 MÉDICO-ÉCO
|
|
|
|
6.6 PUBLICATIONS
|
|
|
|
|
6.7 DMP, BIG DATA & APPLIS
|
|
|
What’s scary, and appealing, about real-world evidence [STAT]
|
|
|
|
|
|
On Tuesday, Herper held a chat with STAT Plus subscribers. Here is an edited partial transcript on the topic, particularly the area of “synthetic controls,” which Herper called “the biggest idea, the most appealing, and the scariest.” It’s the idea that computer-curated sets of health records could sometimes replace placebo groups.
|
|
|
|
|
|
|
6.7.1 IA/BIOINFORMATIQUE
|
|
|
|
Policies designed for drugs won’t work for AI [Nature]
|
|
|
|
|
|
I fear that the guidelines, likely to become a global benchmark, herald a deluge of inadequate policies to regulate AI. The UK code reveals a lack of appreciation for how AI is changing health care, the community and society, instead adhering to conventional assessments of medical interventions’ impacts on individual privacy, safety and efficacy.
|
|
|
|
|
|
|
6.7.3 DMP
|
|
|